X4 Pharmaceuticals Dirección

Dirección controles de criterios 2/4

El CEO de X4 Pharmaceuticals' es Paula Ragan , nombrado en Jul 2014, tiene una permanencia de 9.75 años. compensación anual total es $3.87M, compuesta por 15.1% salario y 84.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.46% de las acciones de la empresa, por valor de $864.53K. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 5.1 años, respectivamente.

Información clave

Paula Ragan

Chief Executive Officer (CEO)

US$3.9m

Compensación total

Porcentaje del salario del CEO	15.1%
Permanencia del CEO	9.8yrs
Participación del CEO	0.5%
Permanencia media de la dirección	3yrs
Promedio de permanencia en la Junta Directiva	5.1yrs

Actualizaciones recientes de la dirección

Recent updates

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Jul 01

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Aug 03

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

Jun 22

X4 Pharmaceuticals EPS misses by $0.44

May 06

How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

Mar 16

X4 Pharmaceuticals EPS misses by $0.12

Nov 05

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paula Ragan en comparación con los beneficios de X4 Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$101m
Sep 30 2023	n/a	n/a	-US$111m
Jun 30 2023	n/a	n/a	-US$131m
Mar 31 2023	n/a	n/a	-US$96m
Dec 31 2022	US$4m	US$583k	-US$96m
Sep 30 2022	n/a	n/a	-US$103m
Jun 30 2022	n/a	n/a	-US$102m
Mar 31 2022	n/a	n/a	-US$100m
Dec 31 2021	US$2m	US$562k	-US$103m
Sep 30 2021	n/a	n/a	-US$85m
Jun 30 2021	n/a	n/a	-US$82m
Mar 31 2021	n/a	n/a	-US$78m
Dec 31 2020	US$3m	US$543k	-US$62m
Sep 30 2020	n/a	n/a	-US$55m
Jun 30 2020	n/a	n/a	-US$55m
Mar 31 2020	n/a	n/a	-US$53m
Dec 31 2019	US$2m	US$492k	-US$53m
Sep 30 2019	n/a	n/a	-US$55m
Jun 30 2019	n/a	n/a	-US$46m
Mar 31 2019	n/a	n/a	-US$40m
Dec 31 2018	US$921k	US$380k	-US$36m

Compensación vs. Mercado: La compensación total de Paula($USD3.87M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.60M).

Compensación vs. Ingresos: La compensación de Paula ha aumentado mientras la empresa no es rentable.

CEO

Paula Ragan (53 yo)

9.8yrs

Permanencia

US$3,872,533

Compensación

Dr. Paula Ragan, Ph D., serves as Director of CAMP4 Therapeutics Corporation since October 2019. She is a Founder of X4 Pharmaceuticals Inc. and serves as its Chief Executive Officer, President and Directo...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paula Ragan	CEO, President & Director	9.8yrs	US$3.87m	0.46% $ 891.3k
Adam Mostafa	CFO, Treasurer & Corporate Secretary	5.6yrs	US$1.88m	0% $ 0
Mary DiBiase	Chief Operating Officer	2.6yrs	US$1.84m	0.17% $ 329.4k
Richard Peters	Founder	no data	sin datos	sin datos
Renato Skerlj	Founder	no data	sin datos	sin datos
Keith Flaherty	Founder & Member of Corporate Advisory Board	no data	sin datos	sin datos
Arthur Taveras	Chief Scientific Officer	3.4yrs	sin datos	0.14% $ 273.0k
Glenn Schulman	Vice President of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Robert Arbeit	Senior Vice President of Clinical Development and Translational Research	no data	sin datos	sin datos
Mark Baldry	Chief Commercial Officer	1.4yrs	sin datos	0.015% $ 28.8k
Christophe Arbet-Engels	Chief Medical Officer	less than a year	sin datos	sin datos

3.0yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de XFOR se considera experimentado (3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paula Ragan	CEO, President & Director	9.8yrs	US$3.87m	0.46% $ 891.3k
Keith Flaherty	Founder & Member of Corporate Advisory Board	8yrs	sin datos	sin datos
Michael Wyzga	Independent Chairman of the Board	5.8yrs	US$95.02k	0.017% $ 33.0k
Gary Bridger	Independent Director	5.1yrs	US$42.73k	0.0020% $ 3.9k
David W. McGirr	Independent Director	6.6yrs	US$61.73k	0.0020% $ 3.9k
Alison Lawton	Independent Director	3.5yrs	US$50.23k	0.0020% $ 3.9k
William Aliski	Independent Director	4.6yrs	US$50.52k	0.0020% $ 3.9k
Michael Vasconcelles	Member of Corporate Advisory Board	8yrs	sin datos	sin datos
Robert Woods	Independent Director	less than a year	sin datos	sin datos
Murray Stewart	Director	5.1yrs	US$45.64k	0.085% $ 166.8k
Francoise de Craecker	Independent Director	2.5yrs	US$47.73k	0.0020% $ 3.9k

5.1yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de XFOR se considera experimentada (5.1 años de antigüedad promedio).

X4 Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

CFO, Treasurer & Corporate Secretary notifies of intention to sell stock

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

Director recently sold US$138k worth of stock

X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

X4 Pharmaceuticals, Inc. Announces Executive Changes

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

Recent updates

X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome

Price target increased by 8.7% to US$3.55

Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Price target increased by 13% to US$3.65

X4 Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Price target decreased by 8.9% to US$3.20

X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

X4 Pharmaceuticals, Inc. Receives A Deficiency Letter from Nasdaq Regarding Bid Price Rule

CFO, Treasurer & Corporate Secretary notifies of intention to sell stock

X4 Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

X4 Pharmaceuticals Announces Submission of New Drug Application (Nda) to U.S. Fda for Mavorixafor in Whim Syndrome

Director recently sold US$138k worth of stock

X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

X4 Pharmaceuticals, Inc. announced that it expects to receive $115 million in funding

X4 Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target increased by 7.5% to US$3.76

X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Price target decreased by 9.5% to US$4.07

Price target decreased by 12% to US$4.21

Consensus revenue estimates fall by 11%

Price target decreased to US$5.08

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

X4 Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Price target increased to US$5.90

X4 Pharmaceuticals Announces Positive Top-Line Results from 4Whim Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in Whim Syndrome

X4 Pharmaceuticals, Inc. Announces Executive Changes

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

X4 Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

X4 Pharmaceuticals: Upcoming Catalysts

X4 Pharmaceuticals, Inc. Announces the Resignation of Derek Meisner from His Position as Chief Legal Officer and Corporate Secretary of the Company, Effective August 22, 2022

X4 Pharmaceuticals, Inc. Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%

X4 Pharmaceuticals, Inc. announced that it expects to receive $55.763275 million in funding from New Enterprise Associates, Inc., Acorn Bioventures, Lumira Ventures, Bain Capital Life Sciences Investors, LLC, OrbiMed Advisors LLC, Hercules Capital, Inc.

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Price target decreased to US$12.36

X4 Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$13.57

Consensus forecasts updated

Price target decreased to US$15.43

X4 Pharmaceuticals, Inc. Presents New Clinical and Scientific Data At 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

Price target decreased to US$18.00

X4 Pharmaceuticals, Inc. Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

Founder notifies of intention to sell stock

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Founder notifies of intention to sell stock

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Microcap Value Index

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021

Founder notifies of intention to sell stock

X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract

X4 Pharmaceuticals, Inc. Provides an Update on its Lead Product Candidate, Mavorixafor, a Novel Small Molecule Currently Being Evaluated in a Phase 3 Clinical Trial

X4 Pharmaceuticals EPS misses by $0.44

How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

X4 Pharmaceuticals, Inc. Provides an Update on Its Lead Product Candidate, Mavorixafor

X4 Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 04, 2021

X4 Pharmaceuticals, Inc. Appoints Diego Cadavid, M.D., as Chief Medical Officer

X4 Pharmaceuticals, Inc. Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of Whim Syndrome

X4 Pharmaceuticals EPS misses by $0.12

X4 Pharmaceuticals, Inc. Announces the Appointment of Art Taveras as Chief Scientific Officer

X4 Pharmaceuticals, Inc. has Re-Assessed the Impacts of the Continuing COVID-19 Pandemic on the Ongoing Phase 1B Dose-Escalation Trial

X4 Pharmaceuticals, Inc. Announces Board Changes, Effective October 5, 2020

X4 Pharmaceuticals, Inc. to Report Q2, 2020 Results on Jul 30, 2020

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell 3000 Growth Index

Análisis de compensación del CEO